CAMBRIDGE, Mass. — Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company focused on immuno-inflammatory and rare diseases, celebrated its first day of trading on Wednesday by ringing the Nasdaq Opening Bell. The event coincided with India’s 79th Independence Day, which the company used to highlight the U.S.-India innovation partnership.
“This is the beginning of the HIND journey — one that anyone in the world can now join thanks to our Nasdaq listing,” said Krishna Gupta, Vyome’s chairman. “Our commitment to shareholders is simple: every decision will be in their best interests. We have no debt, and our board is smart and heavily aligned with shareholders.”
Vyome’s research and development pipeline targets major unmet needs in the $100 billion immuno-inflammatory market. “Our immediate focus will be to unlock the value of our clinical-stage assets, but our vision extends well beyond that,” said Shiladitya Sengupta, founder of Vyome and associate professor of medicine at Harvard Medical School.
Chief Executive Officer Venkat Nelabhotla called the Nasdaq milestone the product of “phenomenal teamwork across continents,” crediting scientists, clinicians, partners, advisors, and key investors. “We are committed to cost-effective operations to create maximal value for shareholders,” he said.
Gupta added that the company was honored to mark Indian Independence Day at Nasdaq, calling it likely a first. “We believe in the special relationship between the U.S. and India, we are a product of it, and we are confident it will be the defining partnership of the next decade — whether in healthcare, AI, or other innovation corridors,” he said.
Maxim Group LLC and Chardan served as financial advisors for the transactions, with legal counsel provided by Fox Rothschild LLP and Sichenzia Ross Ference Carmel LLP.
